[180 Pages Report] The Breast Cancer Diagnostics Market size was estimated at USD 6.54 billion in 2023 and expected to reach USD 7.04 billion in 2024, at a CAGR 7.79% to reach USD 11.06 billion by 2030.
Breast cancer diagnostics refer to tests and procedures conducted to determine the stage of breast cancer, including blood tests, magnetic resonance imaging, Positron emission tomography (PET) scan, and computerized tomography (CT scan). Breast cancer diagnostics tests determine whether the cancer or tumor is restricted to the breast or has spread to other body organs such as lymph nodes. The changing lifestyles and dietary and nutrition regime has led to hormonal changes and caused an increase in the number of women diagnosed with breast cancer and necessitated the development of breast cancer diagnostic tests. Furthermore, government initiatives and incentives to raise awareness about breast cancer and female reproductive health have caused a surge in the number of cancer screening programs worldwide. However, the high costs associated with breast cancer screening tests, genetic testing, and cancer drugs prevent patients from availing the services for treatment and diagnosis of cancer. The lack of skilled personnel to initiate appropriate treatment diagnosis procedures poses significant challenges for cancer care. However, integrating machine learning (ML) and artificial intelligence (AI) in breast cancer diagnostic procedures has enabled early breast cancer diagnosis. AI algorithms can identify missed cancers and breast tissue features and help predict future cancers.
Regional Insights
The American breast cancer diagnostics market is highly developed due to the notable prevalence of breast cancer and the presence of multiple advanced imaging techniques in the region. According to the American Cancer Society, approximately 287,850 new cases of invasive breast cancer were anticipated to be diagnosed in the United States in 2022, bolstering the need for breast cancer diagnosis. Additionally, the growing geriatric population, ongoing cancer-related research activities, and the rising burden of different types of breast cancer have enhanced the need for breast cancer diagnosis in Germany, New Zealand, the United Kingdom, and several other European nations. Moreover, the significant involvement of the European government in breast cancer detection and diagnosis programs has elevated the market scope. In the Asia-Pacific region, China and India are the most prevalent regions for the increasing cases of breast cancer patients, raising the need for breast cancer diagnostics. Furthermore, the emerging campaigns and breast cancer awareness programs have highlighted the need for breast cancer diagnostics in Asian countries.
FPNV Positioning Matrix
The FPNV Positioning Matrix is pivotal in evaluating the Breast Cancer Diagnostics Market. It offers a comprehensive assessment of vendors, examining key metrics related to Business Strategy and Product Satisfaction. This in-depth analysis empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success: Forefront (F), Pathfinder (P), Niche (N), or Vital (V).
Market Share Analysis
The Market Share Analysis is a comprehensive tool that provides an insightful and in-depth examination of the current state of vendors in the Breast Cancer Diagnostics Market. By meticulously comparing and analyzing vendor contributions in terms of overall revenue, customer base, and other key metrics, we can offer companies a greater understanding of their performance and the challenges they face when competing for market share. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With this expanded level of detail, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.
Key Company Profiles
The report delves into recent significant developments in the Breast Cancer Diagnostics Market, highlighting leading vendors and their innovative profiles. These include 4D Path Inc., Abbott Laboratories, Agilent Technologies, Inc., AstraZeneca PLC, Becton, Dickinson and Company, Bio-Rad Laboratories, Inc., Biocept, Inc., Biodesix, Cardinal Health, Danaher Corporation, Epigenomics AG, Exact Sciences Corporation, F. Hoffmann-La Roche Ltd., Fluxion Biosciences Inc. by Cell Microsystems, FUJIFILM Holdings Corporation, General Electric Company, Hologic, Inc., Illumina, Inc., Koninklijke Philips N.V., NanoString Technologies, Inc., NeoGenomics Laboratories, Olea Medical, OncoGenomX, Paragon Biosciences LLC by Catalent, Inc., Provista Diagnostics, Inc. by Todos Medical, Quest Diagnostics Incorporated, Siemens Healthcare Private Limited, and Thermo Fisher Scientific Inc..
Market Segmentation & Coverage
This research report categorizes the Breast Cancer Diagnostics Market to forecast the revenues and analyze trends in each of the following sub-markets:
- Technique
- Imaging
- Analog Mammography
- Breast Ultrasound System
- Digital Mammography
- Mammography
- MRI Scan
- PET/CT Scan
- Molecular Testing
- Tissue Biopsy Tests
- Imaging
- Cancer Type
- BRCA Breast Cancer
- EGFR Mutation Test Breast Cancer
- ER & PR Breast Cancer
- HER 2 Breast Cancer
- Component
- Consumables
- Antibodies
- Kits & Reagents
- Probes
- Instruments
- Biopsy Instruments
- Imaging Instruments
- Pathology-Based Instruments
- Consumables
- Diagnostic Type
- Ionizing Breast Imaging Technologies
- Non-Ionizing Imaging Technologies
- End-User
- Diagnostic Laboratories
- Hospitals & Ambulatory Surgery Center
- Research & Academic Institutes
- Region
- Americas
- Argentina
- Brazil
- Canada
- Mexico
- United States
- California
- Florida
- Illinois
- New York
- Ohio
- Pennsylvania
- Texas
- Asia-Pacific
- Australia
- China
- India
- Indonesia
- Japan
- Malaysia
- Philippines
- Singapore
- South Korea
- Taiwan
- Thailand
- Vietnam
- Europe, Middle East & Africa
- Denmark
- Egypt
- Finland
- France
- Germany
- Israel
- Italy
- Netherlands
- Nigeria
- Norway
- Poland
- Qatar
- Russia
- Saudi Arabia
- South Africa
- Spain
- Sweden
- Switzerland
- Turkey
- United Arab Emirates
- United Kingdom
- Americas
The report offers valuable insights on the following aspects:
- Market Penetration: It presents comprehensive information on the market provided by key players.
- Market Development: It delves deep into lucrative emerging markets and analyzes the penetration across mature market segments.
- Market Diversification: It provides detailed information on new product launches, untapped geographic regions, recent developments, and investments.
- Competitive Assessment & Intelligence: It conducts an exhaustive assessment of market shares, strategies, products, certifications, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players.
- Product Development & Innovation: It offers intelligent insights on future technologies, R&D activities, and breakthrough product developments.
The report addresses key questions such as:
- What is the market size and forecast of the Breast Cancer Diagnostics Market?
- Which products, segments, applications, and areas should one consider investing in over the forecast period in the Breast Cancer Diagnostics Market?
- What are the technology trends and regulatory frameworks in the Breast Cancer Diagnostics Market?
- What is the market share of the leading vendors in the Breast Cancer Diagnostics Market?
- Which modes and strategic moves are suitable for entering the Breast Cancer Diagnostics Market?
US $
Euro €
GBP £
